Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The neuroprotective effects of both BPC-157 and TB-500 are particularly relevant here, as L5 nerve compression can cause foot drop if not addressed
It is also banned by WADA
Clinical findings might include possible pernicious anaemia or neuropathy including subacute combined degeneration of the cord
NNMT is a cytosolic enzyme expressed in adipose tissue, liver, and skeletal muscle
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Great company
US$ 22.16
US$ 29.93
US$ 22.40
US$ 28.35
